Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 73,846,000	$ 70,542,000
Marketable securities	5,192,000	16,784,000
Trade receivables, net	12,943,000	9,811,000
Partnership receivables	831,000	1,790,000
Inventory	1,694,000	1,656,000
Clinical trial retainers	734,000	1,181,000
Other prepaid expenses and other current assets	2,486,000	2,972,000
Total current assets	97,726,000	104,736,000
Property and equipment, net	259,000	276,000
Operating lease right-of-use asset	130,000	178,000
Other assets	100,000	151,000
Total assets	98,215,000	105,341,000
Current liabilities:
Accounts payable	3,014,000	2,712,000
Accrued clinical trial costs and contract research	6,772,000	5,046,000
Accrued compensation and benefits	3,469,000	4,963,000
Other accrued liabilities	7,041,000	5,421,000
Operating lease liability	8,000	11,000
Deferred revenue	0	578,000
Total current liabilities	20,304,000	18,731,000
Loans payable, net of discount	38,189,000	37,960,000
Other liabilities, non-current (Note 6)	2,780,000	2,780,000
Total liabilities	61,273,000	59,471,000
Stockholders’ equity:
Preferred stock, $.001 par value: 5,000 shares authorized at March 31, 2022 and December 31, 2021; no shares issued and outstanding at each of March 31, 2022 and December 31, 2021	0	0
Common stock, $.001 par value: 50,000 shares authorized at March 31, 2022 and December 31, 2021; 34,475 shares issued and outstanding at March 31, 2022 and December 31, 2021	34,000	34,000
Additional paid-in capital	721,653,000	720,386,000
Accumulated other comprehensive gain/(loss)	1,000	(3,000)
Accumulated deficit	(684,746,000)	(674,547,000)
Total stockholders’ equity	36,942,000	45,870,000
Total liabilities and stockholders’ equity	$ 98,215,000	$ 105,341,000